Roche Financial Statements From 2010 to 2024

RHHBY Stock  USD 35.36  0.21  0.59%   
Roche Holding financial statements provide useful quarterly and yearly information to potential Roche Holding Ltd investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Roche Holding financial statements helps investors assess Roche Holding's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Roche Holding's valuation are summarized below:
Roche Holding Ltd does not presently have any trending fundamental ratios for analysis.
Check Roche Holding financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Roche Holding's main balance sheet or income statement drivers, such as , as well as many indicators such as . Roche financial statements analysis is a perfect complement when working with Roche Holding Valuation or Volatility modules.
  
This module can also supplement various Roche Holding Technical models . Check out the analysis of Roche Holding Correlation against competitors.

Roche Holding Ltd OTC Stock Return On Equity Analysis

Roche Holding's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Roche Holding Return On Equity

    
  0.45  
Most of Roche Holding's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Roche Holding Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Roche Holding Ltd has a Return On Equity of 0.4483. This is 101.87% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.

Roche Holding Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Roche Holding's current stock value. Our valuation model uses many indicators to compare Roche Holding value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Roche Holding competition to find correlations between indicators driving Roche Holding's intrinsic value. More Info.
Roche Holding Ltd is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about  0.33  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Roche Holding Ltd is roughly  3.05 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Roche Holding by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Roche Holding's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Roche Holding Financial Statements

Roche Holding investors use historical fundamental indicators, such as Roche Holding's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Roche Holding. Please read more on our technical analysis and fundamental analysis pages.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Holdings operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Roche OTC Stock Analysis

When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.